Short Interest in Synaptogenix, Inc. (NASDAQ:SNPX) Decreases By 37.8%

by · The Cerbat Gem

Synaptogenix, Inc. (NASDAQ:SNPX – Get Free Report) was the target of a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 12,000 shares, a decline of 37.8% from the March 15th total of 19,300 shares. Based on an average daily volume of 12,200 shares, the short-interest ratio is currently 1.0 days. Currently, 0.9% of the shares of the company are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Synaptogenix stock. Geode Capital Management LLC bought a new stake in Synaptogenix, Inc. (NASDAQ:SNPX – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,844 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned approximately 0.80% of Synaptogenix as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 10.34% of the company’s stock.

Synaptogenix Trading Down 5.2 %

NASDAQ:SNPX traded down $0.12 during trading hours on Friday, hitting $2.12. 2,130 shares of the company traded hands, compared to its average volume of 26,546. Synaptogenix has a twelve month low of $1.84 and a twelve month high of $5.38. The firm has a 50-day moving average of $2.61 and a 200 day moving average of $2.92. The stock has a market capitalization of $2.94 million, a price-to-earnings ratio of -0.20 and a beta of 1.07.

Synaptogenix (NASDAQ:SNPX – Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($4.36) EPS for the quarter, missing the consensus estimate of ($2.06) by ($2.30).

About Synaptogenix

(Get Free Report)

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.

See Also